Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'trastuzumab' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 56 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Singletary, SE
      Systemic treatment after sentinel lymph node biopsy in breast cancer: Who,what, and why?

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    2. Kaptain, S; Tan, LK; Chen, BY
      Her-2/neu and breast cancer

      DIAGNOSTIC MOLECULAR PATHOLOGY
    3. van de Vijver, MJ
      Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)

      EUROPEAN JOURNAL OF CANCER
    4. Baselga, J
      Clinical trials of Herceptin (R) (trastuzumab)

      EUROPEAN JOURNAL OF CANCER
    5. Vogel, C; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report

      EUROPEAN JOURNAL OF CANCER
    6. Gieseg, MA; de Bock, C; Ferguson, LR; Denny, WA
      Evidence for epidermal growth factor receptor-enhanced chemosensitivity incombinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

      ANTI-CANCER DRUGS
    7. Hehl, EM
      Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    8. Merimsky, O; Staroselsky, A; Inbar, M; Schwartz, Y; Wigler, N; Mann, A; Marmor, S; Greif, J
      Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer

      ANNALS OF ONCOLOGY
    9. Fountzilas, G; Tsavdaridis, D; Kalogera-Fountzila, A; Christodoulou, C; Timotheadou, E; Kalofonos, C; Kosmidis, P; Adamou, A; Papakostas, P; Gogas, H; Stathopoulos, G; Razis, E; Bafaloukos, D; Skarlos, D
      Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase IIstudy

      ANNALS OF ONCOLOGY
    10. Menard, S; Casalini, P; Campiglio, M; Pupa, S; Agresti, R; Tagliabue, E
      HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

      ANNALS OF ONCOLOGY
    11. Lane, HA; Motoyama, AB; Beuvink, I; Hynes, NE
      Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

      ANNALS OF ONCOLOGY
    12. Baselga, J; Albanell, J
      Mechanism of action of anti-HER2 monoclonal antibodies

      ANNALS OF ONCOLOGY
    13. Leyland-Jones, B; Arnold, A; Gelmon, K; Verma, S; Ayoub, JP; Seidman, A; Dias, R; Howell, J; Rakhit, A
      Pharmacologic insights into the future of trastuzumab

      ANNALS OF ONCOLOGY
    14. Baselga, J
      Phase I and II clinical trials of trastuzumab

      ANNALS OF ONCOLOGY
    15. Eiermann, W
      Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

      ANNALS OF ONCOLOGY
    16. Gianni, L
      Tolerability in patients receiving trastuzumab with or without chemotherapy

      ANNALS OF ONCOLOGY
    17. Bell, R
      Ongoing trials with trastuzumab in metastatic breast cancer

      ANNALS OF ONCOLOGY
    18. Smith, I
      Future directions in the adjuvant treatment of breast cancer: The role of trastuzumab

      ANNALS OF ONCOLOGY
    19. Piccart, MJ
      Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

      ANNALS OF ONCOLOGY
    20. Schaller, G; Evers, K; Papadopoulos, S; Ebert, A; Buhler, H
      Current use of HER2 tests

      ANNALS OF ONCOLOGY
    21. Thor, A
      HER2 - a discussion of testing approaches in the USA

      ANNALS OF ONCOLOGY
    22. Schnitt, SJ
      Breast cancer in the 21st century: Neu opportunities and neu challenges

      MODERN PATHOLOGY
    23. Saijo, N; Tamura, T; Yamamoto, N; Nishio, K
      New strategies for cancer therapy in the 21st century

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    24. Turatti, F; Mezzanzanica, D; Nardini, E; Luison, E; Maffioli, L; Bombardieri, E; de Lalla, C; Canevari, S; Figini, M
      Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    25. Safran, H; Steinhoff, M; Mangray, S; Rathore, R; King, TC; Chai, L; Berzein, K; Moore, T; Iannitti, D; Reiss, P; Pasquariello, T; Akerman, P; Quirk, D; Mass, R; Goldstein, L; Tantravahi, U
      Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    26. Meden, H; Beneke, A; Hesse, T; Novophashenny, I; Wischnewsky, M
      Weekly intravenous recombinant humanized anti-P185(HER2) monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study

      ANTICANCER RESEARCH
    27. Brockhoff, G; Heiss, P; Schlegel, J; Hofstaedter, F; Knuechel, R
      Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells

      CYTOMETRY
    28. Mayfield, S; Vaughn, JP; Kute, TE
      DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines

      BREAST CANCER RESEARCH AND TREATMENT
    29. Mueller-Holzner, E; Fink, V; Frede, T; Marth, C
      Immunohistochemical determination of HER2 expression in breast cancer fromcore biopsy specimens: a reliable predictor of HEr2 status of the whole tumor

      BREAST CANCER RESEARCH AND TREATMENT
    30. Schneider, JW; Chang, AY; Rocco, TP
      Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart

      SEMINARS IN ONCOLOGY
    31. Slichenmyer, WJ; Fry, DW
      Anticancer therapy targeting the ErbB family of receptor tyrosine kinases

      SEMINARS IN ONCOLOGY
    32. Gerber, B; Krause, A; Markmann, S; Reimer, T; Fietkau, R; Muller, H
      Effectiveness of trastuzumab (Herceptin (TM)) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment

      ONCOLOGY
    33. Yarden, Y
      Biology of HER2 and its importance in breast cancer

      ONCOLOGY
    34. Vogel, CL; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line Herceptin (R) monotherapy in metastatic breast cancer

      ONCOLOGY
    35. Winer, EP; Burstein, HJ
      New combinations with Herceptin((R)) in metastatic breast cancer

      ONCOLOGY
    36. Cook-Bruns, N
      Retrospective analysis of the safety of Herceptin((R)) immunotherapy in metastatic breast cancer

      ONCOLOGY
    37. Leyland-Jones, B; Smith, I
      Role of Herceptin (R) in primary breast cancer: Views from North America and Europe

      ONCOLOGY
    38. Rusnak, JM; Kisabeth, RM; Herbert, DP; McNeil, DM
      Pharmacogenomics: Aa clinician's primer on emerging technologies for improved patient care

      MAYO CLINIC PROCEEDINGS
    39. Pilon, SA; Piechocki, MP; Wei, WZ
      Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

      JOURNAL OF IMMUNOLOGY
    40. Bougeret, C; Jiang, SX; Keydar, I; Avraham, H
      Functional analysis of Csk and CHK kinases in breast cancer cells

      JOURNAL OF BIOLOGICAL CHEMISTRY
    41. Uno, M; Otsuki, T; Kurebayashi, J; Sakaguchi, H; Isozaki, Y; Ueki, A; Yata, K; Fujii, T; Hiratsuka, J; Akisada, T; Harada, T; Imajo, Y
      Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma

      INTERNATIONAL JOURNAL OF CANCER
    42. Mann, M; Sheng, HM; Shao, JY; Williams, CS; Pisacane, PI; Sliwkowski, MX; DuBois, RN
      Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

      GASTROENTEROLOGY
    43. Carson, WE; Parihar, R; Lindemann, MJ; Personeni, N; Dierksheide, J; Meropol, NJ; Baselga, J; Caligiuri, MA
      Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

      EUROPEAN JOURNAL OF IMMUNOLOGY
    44. Lyon, E; Millson, A; Lowery, MC; Woods, R; Wittwer, CT
      Quantification of HER2/neu gene amplification by competitive PCR using fluorescent melting curve analysis

      CLINICAL CHEMISTRY
    45. Duffy, MJ
      Biochemical markers in breast cancer: which ones are clinically useful?

      CLINICAL BIOCHEMISTRY
    46. Reilly, RT; Machiels, JPH; Emens, LA; Ercolini, AM; Okoye, FI; Lei, RY; Weintraub, D; Jaffee, EM
      The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

      CANCER RESEARCH
    47. Murillo, H; Schmidt, LJ; Tindall, DJ
      Tyrphostin AGS25 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2

      CANCER RESEARCH
    48. Treish, I; Schwartz, R; Lindley, C
      Pharmacology and therapeutic use of trastuzumab in breast cancer

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    49. Barcus, ME; Powers, CN
      Evaluation of endocrine neoplasms using fine needle aspiration biopsy

      ENDOCRINE PATHOLOGY
    50. Mendelsohn, J; Baselga, J
      The EGF receptor family as targets for cancer therapy

      ONCOGENE
    51. Gilewski, T; Seidman, A; Norton, L; Hudis, C
      An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    52. Brown, RE; Bernath, AM; Levis, GO
      HER-2/neu protein-receptor-positive breast carcinoma: An immunologic perspective

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    53. Carr, JA; Havstad, S; Zarbo, RJ; Divine, G; Mackowiak, P; Velanovich, V
      The association of HER-2/neu amplification with breast cancer recurrence

      ARCHIVES OF SURGERY
    54. Albanell, J; Baselga, J
      The ErbB receptors as targets for breast cancer therapy

      JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
    55. Goldenberg, MM
      Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

      CLINICAL THERAPEUTICS
    56. Beuzeboc, P; Scholl, S; Garau, XS; Vincent-Salomon, A; de Cremoux, P; Couturier, J; Palangie, T; Pouillard, P
      Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene

      BULLETIN DU CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/10/20 alle ore 12:13:26